Sotera Health Company (SHC) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Sotera Health Company (SHC) Healthcare & Pipeline Overview

Sotera Health Company, with a $5.21B market cap, offers sterilization, lab testing, and advisory services to the medical device and biopharmaceutical industries globally. Operating with a 9.9% profit margin and a P/E ratio of 31.85, the company ensures product safety and efficacy across North America, Europe, and other international markets.

What Is the Investment Thesis for SHC?

With a market capitalization of $5.21B and a profit margin of 9.9%, the company demonstrates financial stability. Key value drivers include the increasing demand for sterilization and lab testing services driven by stringent regulatory requirements and growing healthcare spending. The company's diverse service offerings and global presence provide a competitive advantage. Ongoing catalysts include the expansion of its service portfolio and strategic acquisitions to enhance its market position. Potential risks include regulatory changes and increased competition. The company's high beta of 1.88 suggests higher volatility compared to the market.

Based on FMP financials and quantitative analysis

SHC Key Highlights

Market capitalization of $5.21B, reflecting substantial investor confidence in the company's market position and future growth potential.

• P/E ratio of 31.85, indicating a premium valuation based on earnings, driven by strong growth expectations in the healthcare sector.
• Profit margin of 9.9%, showcasing the company's ability to maintain profitability while investing in growth initiatives and service expansion.
• Gross margin of 55.3%, highlighting the efficiency of Sotera Health's operations and the value of its specialized services in sterilization and lab testing.
• Beta of 1.88, suggesting higher volatility compared to the market, potentially offering opportunities for investors seeking higher returns but also indicating increased risk.

Who Are SHC's Competitors?

SHC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are SHC's Key Strengths?

Comprehensive service offerings including sterilization, lab testing, and advisory services.

• Global presence with operations in the United States, Canada, Europe, and other international markets.
• Strong reputation for quality and reliability in the healthcare industry.
• Expertise in navigating complex regulatory requirements.

What Are SHC's Weaknesses?

High beta of 1.88 indicates higher volatility compared to the market.

• Dependence on regulatory compliance, which can be affected by changes in regulations.
• Potential for increased competition in the sterilization and lab testing services market.
• Exposure to potential liabilities related to sterilization processes.

What Could Drive SHC Stock Higher?

Expansion of service portfolio through strategic acquisitions and investments in new technologies.

• Increasing demand for sterilization and lab testing services driven by stringent regulatory requirements.
• Geographic expansion into emerging markets with growing healthcare industries.
• Potential new contracts with major medical device and pharmaceutical companies.
• Development and launch of innovative sterilization and lab testing solutions.

What Are the Key Risks for SHC?

Rich valuation — a P/E of 31.85 runs well above the Healthcare sector’s ~21.50x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $507.2M recently.
• Changes in regulatory requirements that could increase compliance costs.
• Increased competition from other sterilization and lab testing service providers.
• Potential liabilities related to sterilization processes.
• Economic downturns that could reduce demand for healthcare services.
• Dependence on key customers and potential loss of major contracts.

What Are the Growth Opportunities for SHC?

• Expansion of Sterilization Services: Sotera Health can capitalize on the growing demand for sterilization services driven by the increasing volume of medical devices and pharmaceuticals. By investing in advanced sterilization technologies and expanding its capacity, Sotera Health can increase its market share and revenue. This includes gamma and electron beam irradiation, and ethylene oxide (EO) processing.
• Enhancement of Lab Testing Capabilities: The company can further enhance its lab testing capabilities through Nelson Labs, focusing on microbiological and analytical chemistry testing. The market for these services is expanding due to stringent regulatory requirements and the need for accurate and reliable testing. By offering a broader range of testing services and investing in advanced equipment, Sotera Health can attract more clients and increase its revenue.
• Geographic Expansion: Sotera Health can expand its geographic presence by targeting emerging markets with growing healthcare industries. These markets offer significant opportunities for sterilization and lab testing services. By establishing partnerships and strategic alliances, Sotera Health can penetrate these markets and establish a strong foothold. This includes expansion in Asia-Pacific and Latin America.
• Strategic Acquisitions: Sotera Health can pursue strategic acquisitions to expand its service portfolio and geographic reach. By acquiring companies with complementary capabilities, Sotera Health can enhance its competitive position and offer a more comprehensive suite of services. This includes acquiring companies specializing in advanced sterilization technologies or niche testing services.
• Advisory Services Growth: Sotera Health can focus on growing its advisory services, providing expertise to medical device and biopharmaceutical companies. The demand for advisory services is increasing as companies navigate complex regulatory requirements and seek to improve their product development processes. By offering specialized advisory services, Sotera Health can generate additional revenue and strengthen its relationships with clients.

What Are SHC's Competitive Advantages?

• Specialized Expertise: Sotera Health possesses deep expertise in sterilization, lab testing, and advisory services, creating a barrier to entry for new competitors.
• Regulatory Compliance: The company's adherence to stringent regulatory standards ensures high-quality services and builds trust with clients.
• Global Presence: Sotera Health's global footprint allows it to serve clients in multiple regions, providing a competitive advantage over smaller, regional players.
• Comprehensive Service Offering: The company's comprehensive suite of services, including sterilization, lab testing, and advisory, provides a one-stop solution for clients.

What Does SHC Do?

Sotera Health Company, established in 2017 and headquartered in Broadview Heights, Ohio, is a global provider of sterilization, lab testing, and advisory services. Originally incorporated as Sotera Health Topco, Inc., the company rebranded in October 2020 to Sotera Health Company. Its services are critical for ensuring the safety and efficacy of medical devices, pharmaceuticals, and other healthcare products. Sotera Health operates through three primary service lines: sterilization, lab testing via Nelson Labs, and advisory services. The sterilization segment includes gamma and electron beam irradiation, and ethylene oxide (EO) processing. Nelson Labs provides microbiological and analytical chemistry testing. The advisory services offer expertise to medical device and biopharmaceutical companies. Sotera Health serves a diverse range of industries, including medical devices, pharmaceuticals, food and agriculture, and commercial, advanced, and specialty applications. The company's global footprint extends across the United States, Canada, Europe, and other international markets, supporting the healthcare industry with essential safety and quality assurance services.

What Products and Services Does SHC Offer?

• Provides gamma and electron beam irradiation sterilization services.
• Offers ethylene oxide (EO) processing for sterilization.
• Conducts microbiological and analytical chemistry testing through Nelson Labs.
• Provides advisory services to medical device and biopharmaceutical industries.
• Ensures the safety and efficacy of medical devices and pharmaceuticals.
• Serves medical device, pharmaceutical, food, and agricultural industries.
• Offers commercial, advanced, and specialty application services.

How Does SHC Make Money?

• Generates revenue through sterilization services, including gamma and electron beam irradiation, and EO processing.
• Earns revenue from lab testing services provided by Nelson Labs, including microbiological and analytical chemistry testing.
• Provides advisory services to medical device and biopharmaceutical companies for a fee.
• Serves a diverse range of industries, including medical devices, pharmaceuticals, food and agriculture, and commercial applications.

What Industry Does SHC Operate In?

Sotera Health Company operates within the medical diagnostics and research industry, a sector characterized by stringent regulatory standards and increasing demand for safety and quality assurance. The global sterilization services market is projected to grow, driven by the increasing volume of medical devices and pharmaceuticals. Sotera Health competes with companies offering similar sterilization and lab testing services. The company's comprehensive service offerings and global presence provide a competitive edge in this fragmented market. Key trends include the adoption of advanced sterilization technologies and the increasing outsourcing of testing and advisory services.

Who Are SHC's Key Customers?

• Medical device manufacturers requiring sterilization services.
• Pharmaceutical companies needing lab testing and sterilization.
• Food and agricultural companies seeking sterilization for their products.
• Commercial, advanced, and specialty application industries.

Company Profile

Sotera Health Company operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Broadview Heights, US. The company is led by CEO Alton E. Shader. SHC has traded publicly since 2020.

Sotera Health Company Financial Trajectory

Sotera Health Company (SHC) reported $321.4M in revenue for Q2 FY2026, reflecting 14.8% growth compared to the prior quarter. The company recorded net income of $53.6M, with diluted EPS of $0.19. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, SHC averaged $0.14 in diluted EPS.

How Sotera Health Company Is Valued

Sotera Health Company carries a market capitalization of $5.21B, placing it in the mid-cap category. Analyst price targets span from $18.00 to $25.00, with a consensus of $20.50. At the current price of $18.26, that implies approximately 12% upside potential. Relative to its peer group, SHC's quantitative score of 76/100 is above the peer average of 56/100.

Return on equity for Sotera Health Company stands at 26.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 4.9%, showing how much profit it generates from its asset base. SHC trades at a trailing price-to-earnings ratio of 31.85, above the Healthcare sector average of ~21.50x. Its free cash flow yield is 2.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.80 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 3.1%, the inverse of the P/E and a quick read on earnings relative to price.

Sotera Health Company's Piotroski F-Score is 7/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 1.91 places it in the grey zone, a middle ground that warrants monitoring.

Sotera Health Company has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 8.1% above estimates on average.

Over the past six months, Sotera Health Company insiders filed 20 SEC Form 4 transactions — 7 sales and 13 purchases. On net that is roughly 32.3M shares disposed (about $507.2M), a signal worth weighing alongside the fundamentals.

SHC Financials

SHC Latest News

SHC Analyst Consensus

SHC MoonshotScore

SHC Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources